专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007016597A3 TARGETING TNF-ALPHA CONVERTING ENZYME (TACE)-DEPENDENT GROWTH FACTOR SHEDDING IN CANCER THERAPY 审中-公开
公开(公告)号：WO2007016597A3
公开(公告)日：2007-02-08
申请号：PCT/US2006/030008
申请日：2006-07-31
申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA , KENNY, Paraic, A. , BISSELL, Mina, J.
发明人： KENNY, Paraic, A. , BISSELL, Mina, J.
IPC分类号： C12N15/09
摘要： The invention provides methods for modulating tumor cell proliferation by contacting a cell (e g tumor cell) with a TACE inhibitor and a compound that inhibits EGFR tyrosine kinase, whereby the TACE inhibitor enhances the sensitivity of the cell to the EGFR tyrosine kinase inhibitor Additionally, methods for treating cancer and methods for identifying TACE inhibitors are also provided

2. 发明申请

WO2010120554A1 DETECTING AND TREATING BREAST CANCER RESISTANCE TO EGFR INHIBITORS 审中-公开
标题翻译：检测和治疗EGFR抑制剂对乳腺癌的抵抗力
公开(公告)号：WO2010120554A1
公开(公告)日：2010-10-21
申请号：PCT/US2010/029497
申请日：2010-03-31
申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA , MOONLEE, Sun-Young , KENNY, Paraic, A. , LENBURG, Marc, E. , XU, Ren , BISSELL, Mina, J. , FURUTA, Saori , MEIER, Roland
发明人： MOONLEE, Sun-Young , KENNY, Paraic, A. , LENBURG, Marc, E. , XU, Ren , BISSELL, Mina, J. , FURUTA, Saori , MEIER, Roland
IPC分类号： G01N33/53 , C07K16/00
CPC分类号： C07K16/3015
摘要： The application describes therapeutic compositions and methods for treating cancer. For example, therapeutic compositions and methods related to inhibition of FAM83A (family with sequence similarity 83) are provided. The application also describes methods for diagnosing cancer resistance to EGFR inhibitors. For example, a method of diagnosing cancer resistance to EGFR inhibitors by detecting increased FAM83A levels is described.
摘要翻译：本申请描述了用于治疗癌症的治疗组合物和方法。例如，提供了与抑制FAM83A（具有序列相似性83的家族）相关的治疗组合物和方法。本申请还描述了用于诊断对EGFR抑制剂的耐癌性的方法。例如，描述了通过检测增加的FAM83A水平来诊断对EGFR抑制剂的耐癌性的方法。

3. 发明申请

WO2008140587A2 RHAMM, A CO-RECEPTOR AND ITS INTERACTIONS WITH OTHER RECEPTORS IN CANCER CELL MOTILITY AND THE IDENTIFICATION OF CANCER PROGNITOR CELL POPULATIONS 审中-公开
标题翻译：癌症患者，受体及其与癌细胞中其他受体的相互作用及癌细胞群体细胞的鉴定
公开(公告)号：WO2008140587A2
公开(公告)日：2008-11-20
申请号：PCT/US2007/085462
申请日：2007-11-21
申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA , LAWSON HEALTH RESEARCH INSTITUTE , TURLEY, Eva, A. , BISSELL, Mina, J. , WINNIK, Francoise
发明人： TURLEY, Eva, A. , BISSELL, Mina, J. , WINNIK, Francoise
IPC分类号： G01N33/574
CPC分类号： C07K16/2896
摘要： CD44 is an integral hyaluronan receptor that can either promote or inhibit motogenic signaling in tumor cells. Rhamm is a non-integral cell surface (CD 168) and intracellular hyaluronan binding protein that promotes cell motility in vitro and whose expression is strongly upregulated in aggressive tumors. The present invention describes compositions and methods for the prognosis and diagnosis of cancer by the detection of CD44/Rhamm complexes. The use of labeled Rhamm-binding agents in culture and in vivo to identify tumorigenic progenitor cells that exhibit an aggressive phenotype characterized by high Rhamm and CD44 expression is further described. Specific methods include using hyaluronan to target imaging or therapeutic agents to these progenitor tumor subsets in breast and likely other cancers.
摘要翻译： CD44是一种完整的透明质酸受体，可以在肿瘤细胞中促进或抑制机体生成信号。 Rhamm是一种非整体细胞表面（CD168）和细胞内透明质酸结合蛋白，其促进体外细胞运动，其表达在侵袭性肿瘤中强烈上调。本发明描述了通过检测CD44 / Rhamm复合物来预测和诊断癌症的组合物和方法。进一步描述了在培养和体内使用标记的Rhamm结合剂来鉴定以高Rhamm和CD44表达为特征的侵袭性表型的致瘤性祖细胞。具体方法包括使用透明质酸靶向成像或治疗剂到乳腺和可能的其他癌症中的这些祖细胞肿瘤亚群。

4. 发明申请

WO2008140586A3 MODULATION OF RHAMM (CD168) FOR SELECTIVE ADIPOSE TISSUE DEVELOPMENT 审中-公开
公开(公告)号：WO2008140586A3
公开(公告)日：2008-11-20
申请号：PCT/US2007/085453
申请日：2007-11-21
申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA , LAWSON HEALTH RESEARCH INSTITUTE , TURLEY, Eva, A. , BISSELL, Mina, J.
发明人： TURLEY, Eva, A. , BISSELL, Mina, J.
IPC分类号： A61K38/00
摘要： Herein is described the methods and compositions for modulation of Rhamm, also known as CD 186, and its effects on wound repair, muscle differentiation, bone density and adipogeneisis through its ability to regulate mesenchymal stem cell differentiation. Compositions and methods are provided for blocking Rhamm function for selectively increasing subcutaneous, but not, visceral fat. Compositions and methods for modulating Rhamm in wound repair are also described.

5. 发明申请

WO2014186782A2 SCALABLE ORGANOTYPIC MODELS OF TUMOR DORMANCY 审中-公开
标题翻译：肿瘤多发性的可扩展有机模型
公开(公告)号：WO2014186782A2
公开(公告)日：2014-11-20
申请号：PCT/US2014/038514
申请日：2014-05-17
申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA , GHAJAR, Cyrus, M. , BISSELL, Mina, J.
发明人： GHAJAR, Cyrus, M. , BISSELL, Mina, J.
IPC分类号： C12N5/095 , C12Q1/68
CPC分类号： C12N5/0697 , C12N5/0691 , C12N2502/13 , C12N2502/28 , C12N2502/30 , G01N33/5011 , G01N33/5044 , G01N33/5064
摘要： Herein are described synthetic organotypic microvascular niches formed by self- assembly of stromal cells cultured endothelial cells seeded with cells of interest to model and determine dormancy state of these cells of interest in these tissues. These models demonstrated that endothelial-derived thrombospondin-1 induces sustained cancer cell quiescence. We further describe dormancy models, and identified active tumor-promoting, endothelial tip cell-derived factors. Our work reveals that stable microvasculature constitutes a "dormant niche, " whereas sprouting neovasculature sparks micrometastatic outgrowth.
摘要翻译：本文描述了通过用培养的感兴趣的细胞接种的培养的内皮细胞的基质细胞的自组装形成的合成的器官型微血管生态位，以模拟和确定这些组织中这些感兴趣的细胞的休眠状态。这些模型证明内皮衍生的血小板反应蛋白-1诱导持续的癌细胞静止。我们进一步描述了休眠模型，并确定了活化的肿瘤促进，内皮细胞来源的因子。我们的工作表明，稳定的微血管组成了一个“休眠的利基”，而萌发的新生血管发生微转移的生长。

6. 发明申请

WO2012031015A1 CELL CULTURE SCREEN FOR AGENTS THAT CONTROL ADIPOGENESIS AND MYOFIBROBLAST DIFFERENTIATION 审中-公开
标题翻译：用于控制成虫和MYOFIBROBLAST差异的细胞的细胞培养屏幕
公开(公告)号：WO2012031015A1
公开(公告)日：2012-03-08
申请号：PCT/US2011/050054
申请日：2011-08-31
申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA , BISSELL, Mina, J. , TURLEY, Eva, A. , BAHRAMI, Seyed Bahram
发明人： BISSELL, Mina, J. , TURLEY, Eva, A. , BAHRAMI, Seyed Bahram
IPC分类号： C12N5/071
CPC分类号： G01N33/5073 , A61K49/0008 , C12N5/0653 , C12N2503/02 , G01N33/5044
摘要： Methods are provided for the rapid and robust screening test agents for adipogenic activity. Agents testing positive in the assays are good candidate agents for wrinkle reduction, normalizing skin appearance after reconstructive or cosmetic surgery, e.g., grafted tissue on burn victims, normalizing skin appearance during and after wound healing, and the like. In certain embodiments the methods involve providing mammalian test cells with adipogenic potential wherein said cells are primed for, but withheld from differentiation into adipocytes; contacting the cells with the test agent(s); and screening said test cells for an adipocyte phenotype wherein the presence of a feature characteristic of an adipocyte is an indicator that said test agent is adipogenic.
摘要翻译：为快速而有力的筛选试验剂提供了脂肪生成活性的方法。在测定中测试阳性的试剂是用于皱纹减少，重建或整容手术后的皮肤外观正常化，例如烧伤受害者上的移植组织，伤口愈合期间和伤口愈合之后的皮肤外观正常化的良好候选试剂。在某些实施方案中，所述方法涉及提供具有成脂潜能的哺乳动物测试细胞，其中所述细胞被引发，但不被分化成脂肪细胞; 使细胞与测试剂接触; 以及筛选所述测试细胞的脂肪细胞表型，其中脂肪细胞特征特征的存在是所述测试试剂是脂肪形成的指示剂。

7. 发明申请

WO2011050342A2 RATIONAL DESIGN OF A BIOCOMPATIBLE SYNTHETIC LAMININ-111 POLYMER AND USES THEREOF 审中-公开
标题翻译：生物相容性合成型层粘连蛋白-111聚合物的合理设计及其应用
公开(公告)号：WO2011050342A2
公开(公告)日：2011-04-28
申请号：PCT/US2010/053877
申请日：2010-10-22
申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA , LA BARGE, Mark, A. , GHAJAR, Cyrus, M. , HEALY, Kevin, E. , BISSELL, Mina, J.
发明人： LA BARGE, Mark, A. , GHAJAR, Cyrus, M. , HEALY, Kevin, E. , BISSELL, Mina, J.
IPC分类号： A61K38/17
CPC分类号： A61K38/39 , A61K47/60 , A61L27/18
摘要： The present invention identifies and provides the minimal unit of function for laminin-111 (Ln-1) to inform the design of synthetic basement membranes that could function in lieu of Ln-1. Small linear peptides that correspond to different receptor binding domains of Ln-1 were identified as crucial mediators of milk protein promoter activity, apical polarity, and alveogenesis. The peptides were conjugated to the biopolymer hyaluronic acid and combined with a hydrogel to create a synthetic analog of the Ln-I molecule. Specific combinations of the peptide conjugates synergistically mediated milk-protein promoter activity. Thus, we have succeeded in identifying the minimum unit of function within Ln-1 responsible for mediating a number of essential mammary functions.
摘要翻译：本发明鉴定并提供层粘连蛋白-111（Ln-1）的最小功能单位，以通知设计可代替Ln-1发挥功能的合成基膜。对应于Ln-1的不同受体结合结构域的小线性肽被鉴定为乳蛋白启动子活性，顶端极性和肺泡形成的关键介质。肽与生物聚合物透明质酸缀合并与水凝胶结合以产生Ln-1分子的合成类似物。肽缀合物的特定组合协同介导的乳蛋白启动子活性。因此，我们成功地确定了Ln-1中负责调解一些基本乳腺功能的最小功能单位。

8. 发明申请

WO2010148370A1 14-3-3 SIGMA AS A BIOMARKER OF BASAL BREAST CANCER 审中-公开
标题翻译： 14-3-3 SIGMA作为基础乳腺癌的生物标志物
公开(公告)号：WO2010148370A1
公开(公告)日：2010-12-23
申请号：PCT/US2010/039276
申请日：2010-06-18
申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA , BOUDREAU, Aaron, T. , BISSELL, Mina, J.
发明人： BOUDREAU, Aaron, T. , BISSELL, Mina, J.
IPC分类号： G01N33/574
CPC分类号： G01N33/57415 , G01N2333/4703
摘要： 14-3-3sigma was initially described as a breast tumor suppressor silenced in about 80% of tumors. However, we show 14-3-3sigma expression correlates with acquisition of tumorigenicity and invasiveness, and that 14-3-3sigma coordinates directional cell migration by directly inhibiting actin polymerization (in vitro and in situ) downstream of canonical signaling pathways, thus defining regions of actin assembly within cells. By immunohistochemical analysis, 14-3-3sigma emerged as a highly sensitive and specific basal breast cancer biomarker, which when present, correlates with metastasis and poor outcome in independent patient cohorts. These data suggest that targeting 14-3-3sigma-regulated actin cytoskeletal dynamics may benefit patients having the basal-like breast cancer subtype.
摘要翻译：最初将14-3-3sigma描述为在约80％的肿瘤中沉默的乳腺肿瘤抑制因子。然而，我们显示14-3-3sigma表达与获得致瘤性和侵袭性相关，14-3-3sigma通过直接抑制规范信号通路下游的肌动蛋白聚合（体外和原位）来协调定向细胞迁移，从而定义区域的细胞内的肌动蛋白组装。通过免疫组织化学分析，14-3-3sigma作为高度敏感和特异性的基底乳腺癌生物标志物出现，当存在时，与独立患者队列中的转移和不良结果相关。这些数据表明靶向14-3-3sigma调节的肌动蛋白细胞骨架动力学可能有利于患有基底样乳腺癌亚型的患者。

9. 发明申请

WO2006130472A2 IDENTIFICATION OF RAC1B AS A MARKER AND MEDIATOR OF MATRIX METALLOPROTEINASE-INDUCED MALIGNANCY 审中-公开
标题翻译：鉴定RAC1B作为基质金属蛋白酶诱导的恶性肿瘤的标记物和介质
公开(公告)号：WO2006130472A2
公开(公告)日：2006-12-07
申请号：PCT/US2006/020467
申请日：2006-05-26
申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA , RADISKY, Derek, C. , NELSON, Celeste, M. , BISSELL, Mina, J.
发明人： RADISKY, Derek, C. , NELSON, Celeste, M. , BISSELL, Mina, J.
CPC分类号： G01N33/574 , G01N2333/4719 , G01N2333/8146
摘要： The present invention provides compositions and methods for detecting MMP-induced malignancies by detecting Rac1b expression. The invention further provides compositions and in vitro and in vivo methods for inhibiting MMP-induced malignant transformation by modulating Rac1b expression and/or function.
摘要翻译：本发明提供通过检测Rac1b表达来检测MMP诱导的恶性肿瘤的组合物和方法。本发明还提供了通过调节Rac1b表达和/或功能来抑制MMP诱导的恶性转化的组合物和体外和体内方法。

10. 发明公开

EP2922869A2 PEPTIDES THAT STIMULATE SUBCUTANEOUS ADIPOGENESIS 有权
标题翻译：肽类抗氧化剂亚科植物
公开(公告)号：EP2922869A2
公开(公告)日：2015-09-30
申请号：EP13802811.3
申请日：2013-11-25
申请人： The Regents of the University of California
发明人： TURLEY, Eva, A. , BAHRAMI, Seyed, Bahram , BISSELL, Mina, J.
IPC分类号： C07K14/705 , C07K7/04 , A61K38/17 , A61K38/03
CPC分类号： C07K7/08 , A61K8/64 , A61K31/167 , A61K38/00 , A61K38/03 , A61K38/08 , A61Q19/001 , A61Q19/08 , C07K7/06 , C07K14/70596
摘要： Peptides of 5 to 14 amino acids in length that stimulate subcutaneous adipogenesis in mammals and uses thereof are provided.
摘要翻译：提供长度为5至14个氨基酸的刺激皮下脂肪生成的肽及其用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式